A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis (AtDventure)
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis
Sponsor: GlaxoSmithKline
Terminated
Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.
Other terminated trials from GlaxoSmithKline
Other Dermatitis, Atopic trials with similar outcome
This PHASE2 trial investigates Dermatitis, Atopic and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 19 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
19 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE2
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 14 earlier versions
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alicante, Spain , Ansan, South Korea , Athens, Greece , Bangkok, Thailand , Bari, Italy , Barrie, Canada , Beijing, China , Berlin, Germany , Bologna, Italy , Buenos Aires, Argentina and 67 more locations